EGFR and cancer: For non-small cell lung cancers (NSCLC), specifically those without targetable mutations in the epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK), immune checkpoint inhibitors, specifically the antibodies that target programmed cell death 1 (PD-1) or programmed death ligand 1 (PD-L1), have revolutionized cancer therapy even though response rates are relatively low [3].